BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250327T190000
DTEND;TZID=Africa/Nairobi:20250327T203000
DTSTAMP:20260527T102701
CREATED:20250611T191852Z
LAST-MODIFIED:20250622T142307Z
UID:38875-1743102000-1743107400@kesho-kenya.org
SUMMARY:Management of Kidney Cancer
DESCRIPTION:Moderator: Dr Jonathan Wala \nSpeakers & Topics: \n\nDr Amina K. Habib: Optimizing Kidney Cancer Care\nDr Patrick Mbuthia: Surgical Aspects of Kidney Cancer Management\n\nDiagnosis and Evaluation \n– RCC includes clear cell\, papillary\, chromophobe\, and rare subtypes.\n– Classic triad (flank pain\, hematuria\, mass) is rare and suggests late-stage disease.\n– Paraneoplastic syndromes present in ~30% of cases.\n– Imaging: Ultrasound (cystic lesions)\, MRI/CT (staging)\, and renal function tests.\n– Renal biopsy recommended for indeterminate lesions\, small masses for surveillance\, or metastatic confirmation. \nSurgical Management \n– Partial nephrectomy preferred in localized RCC for nephron-sparing and better long-term outcomes.\n– Thrombectomy improves survival in non-metastatic RCC with IVC involvement.\n– Cytoreductive nephrectomy and metastasectomy have roles in selected metastatic cases. \n Upper Tract Urothelial Carcinoma (UTUC) \n– Represents 5–10% of urothelial cancers\, commonly presents with hematuria.\n– Risk factors: smoking\, aristolochic acid\, arsenic exposure\, Lynch syndrome.\n– Diagnostic tools: CT/MRI\, cystoscopy\, urinary cytology\, retrograde pyelography\, ureteronephroscopy. \nManagement of UTUC \n– Low-risk: Endoscopic ablation + topical chemotherapy.\n– High-risk localized: Radical nephroureterectomy + bladder cuff removal\, postoperative intravesical chemotherapy.\n– Role of lymph node dissection and neoadjuvant chemotherapy is still being defined.
URL:https://kesho-kenya.org/event/management-of-kidney-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/Kidney-Cancer-e1749669450937.jpg
END:VEVENT
END:VCALENDAR